Erythroderma in Tuberculosis Therapy: A Case of Isoniazid-Induced Skin Toxicity

Introduction: Tuberculosis continues to pose a considerable public health challenge in India. Although antitubercular drugs are vital for effective treatment, they can lead to significant adverse reactions, one of which is drug-induced erythroderma. This severe inflammatory skin disorder is marked by extensive erythema and scaling that can affect more than 80% of the body�s surface area. Case Presentation: We present a 75-year-old male who was admitted with a onemonth history of widespread skin redness and scaling, accompanied by loose stools for the past three days. He had been undergoing antitubercular treatment for tuberculosis for 5 months. A thorough cutaneous examination revealed numerous erythematous, hyperpigmented plaques exhibiting scaling and superficial fissures, affecting the entire face, with some lesions on the lower lip, as well as hyperpigmented patches on the buccal mucosa and lower extremities. The patient also reported experiencing itching for the last 20 days and complained of bleeding per rectum while passing stools over the past three days. Management and Outcome: Given the clinical findings and the patient�s history of antitubercular medication use a diagnosis of erythroderma, secondary to isoniazid was established after rechallenging. The patient�s antitubercular regimen was modified, and he received supportive treatment aimed at enhancing skin barrier function and reducing inflammation. Discussion and Conclusion: This case underscores the necessity of recognizing drug-induced erythroderma in patients undergoing antitubercular therapy who exhibit extensive skin involvement. Timely diagnosis and effective management of the underlying condition, along with supportive care, are essential for enhancing patient outcomes.

View article page

Download PDF